Your browser doesn't support javascript.
loading
Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study.
Esser, Peter; Müller, Horst; Borchmann, Peter; Kreissl, Stefanie; Knoop, Hans; Platzbecker, Uwe; Vucinic, Vladan; Mehnert-Theuerkauf, Anja.
Afiliação
  • Esser P; Department of Medical Psychology and Medical Sociology, University of Leipzig, Philipp-Rosenthal-Straße 55, 04103, Leipzig, Germany. peter.esser@medizin.uni-leipzig.de.
  • Müller H; German Hodgkin Study Group (GHSG), Clinic I for Internal Medicine at the University Medical Center of Cologne, Cologne, Germany.
  • Borchmann P; German Hodgkin Study Group (GHSG), Clinic I for Internal Medicine at the University Medical Center of Cologne, Cologne, Germany.
  • Kreissl S; German Hodgkin Study Group (GHSG), Clinic I for Internal Medicine at the University Medical Center of Cologne, Cologne, Germany.
  • Knoop H; Department of Medical Psychology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, Netherlands.
  • Platzbecker U; Clinic for Hematology, Cellular Therapy and Hemostaseology, University Medical Center Leipzig, Leipzig, Germany.
  • Vucinic V; Clinic for Hematology, Cellular Therapy and Hemostaseology, University Medical Center Leipzig, Leipzig, Germany.
  • Mehnert-Theuerkauf A; Department of Medical Psychology and Medical Sociology, University of Leipzig, Philipp-Rosenthal-Straße 55, 04103, Leipzig, Germany.
J Clin Psychol Med Settings ; 30(4): 856-865, 2023 12.
Article em En | MEDLINE | ID: mdl-36808045
We investigated the feasibility of a web-based cognitive-behavioral therapy to reduce cancer-related fatigue (CRF) among survivors of Hodgkin lymphoma. In this before-and-after trial, patients were primarily recruited via the German Hodgkin Study Group (GHSG). We assessed feasibility (response and drop-out rate) and preliminary efficacy including CRF, quality of life (QoL), and depressive symptomatology. T tests compared baseline levels with t1 (post treatment) and t2 (3 months of follow-up). Among 79 patients contacted via the GHSG, 33 provided interest (42%). Among the seventeen participants, four were treated face-to-face (pilot patients), 13 underwent the web-based version. Ten patients completed the treatment (41%). Among all participants, CRF, depressive symptomatology, and QoL improved at t1 (p ≤ .03). The effect in one of the CRF measures remained at t2 (p = .03). Except for QoL, post-treatment effects were replicated among the completers of the web-based version (p ≤ .04). The potential for this program has been demonstrated, but needs to be re-assessed after identified issues on feasibility have been resolved.Trial registration: The study was registered at ClinicalTrials.gov (Number: NCT03968250).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Terapia Cognitivo-Comportamental Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Terapia Cognitivo-Comportamental Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article